LBPEC-01 is under clinical development by Locus Biosciences and currently in Phase III for Urinary Tract Infections. According to GlobalData, Phase III drugs for Urinary Tract Infections have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how LBPEC-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LBPEC-01 is under development for the treatment of urinary tract infections caused by Escherichia coli (E. coli) and asymptomatic bacteriuria. The drug candidate is a CRISPR-engineered bacteriophage (crPhage) developed based on CRISPR-Cas3 technology. It is administered through intravenous route.
Locus Biosciences overview
Locus Biosciences (Locus) is biotechnology company that develop and commercialize antimicrobial therapeutics for antibiotic-resistant bacterial infections and microbiome-related disorders. The company harnesses CRISPR Cas3-engineered phage (crPhage) platform for developing its products. crPhage products kills the DNA of target bacteria cells, including antibiotic-resistant superbugs, while leaving non-targeted species unharmed. Locus is developing CRISPR-Cas3 enzymes targeting pathogens, such as pseudomonas aeruginosa, clostridium difficile, escherichia coli and staphylococcus aureus. The company works in collaboration with academic, research and pharmaceutical companies to develop its product portfolio. Locus is headquartered in Morrisville, North Carolina, the US.
For a complete picture of LBPEC-01’s drug-specific PTSR and LoA scores, buy the report here.